Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
COVID-19
Glycemia
Metformin
Polycystic ovary syndrome
Prediabetes
Journal
Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
08
09
2022
revised:
03
11
2022
accepted:
09
11
2022
pubmed:
19
11
2022
medline:
15
12
2022
entrez:
18
11
2022
Statut:
ppublish
Résumé
Studies suggest that metformin is associated with reduced COVID-19 severity in individuals with diabetes compared to other antihyperglycemics. We assessed if metformin is associated with reduced incidence of severe COVID-19 for patients with prediabetes or polycystic ovary syndrome (PCOS), common diseases that increase the risk of severe COVID-19. This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls). After balancing via inverse probability score weighting, associations with COVID-19 severity were assessed by logistic regression. In the prediabetes cohort, when compared to levothyroxine, metformin was associated with a significantly lower incidence of COVID-19 with "mild-ED" or worse (OR [95% CI]: 0.636, [0.455-0.888]) and "moderate" or worse severity (0.493 [0.339-0.718]). Compared to ondansetron, metformin was associated with lower incidence of "mild-ED" or worse severity (0.039 [0.026-0.057]), "moderate" or worse (0.045 [0.03-0.069]), "severe" or worse (0.183 [0.077-0.431]), and "mortality/hospice" (0.223 [0.071-0.694]). For PCOS, metformin showed no significant differences in severity compared to levothyroxine, but was associated with a significantly lower incidence of "mild-ED" or worse (0.101 [0.061-0.166]), and "moderate" or worse (0.094 [0.049-0.18]) COVID-19 outcome compared to ondansetron. Metformin use is associated with less severe COVID-19 in patients with prediabetes or PCOS.
Identifiants
pubmed: 36400170
pii: S0168-8227(22)00971-8
doi: 10.1016/j.diabres.2022.110157
pmc: PMC9663381
pii:
doi:
Substances chimiques
Metformin
9100L32L2N
Hypoglycemic Agents
0
Thyroxine
Q51BO43MG4
Types de publication
Observational Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110157Subventions
Organisme : NIH HHS
ID : R24 OD011883
Pays : United States
Organisme : NCATS NIH HHS
ID : U24 TR002306
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Published by Elsevier B.V.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Clin Endocrinol (Oxf). 2017 Jan;86(1):1-6
pubmed: 27664414
J Clin Endocrinol Metab. 1996 Aug;81(8):2854-64
pubmed: 8768842
BMC Med Res Methodol. 2021 Jul 5;21(1):136
pubmed: 34225653
Exp Biol Med (Maywood). 2021 Feb;246(4):369-370
pubmed: 33215530
Pharmacol Rep. 2020 Dec;72(6):1479-1508
pubmed: 32889701
J Med Virol. 2021 Jul;93(7):4273-4279
pubmed: 33580540
Hum Reprod. 2016 Dec;31(12):2841-2855
pubmed: 27664216
Front Pharmacol. 2022 Mar 09;13:784459
pubmed: 35370738
Biom J. 2021 Mar;63(3):528-557
pubmed: 33314251
Drugs Real World Outcomes. 2022 Sep;9(3):359-375
pubmed: 35809196
J Clin Invest. 2010 Jul;120(7):2355-69
pubmed: 20577053
Diabetes Metab Syndr. 2022 May;16(5):102464
pubmed: 35508091
BMC Med. 2020 Jul 15;18(1):220
pubmed: 32664957
J Physiol Pharmacol. 2019 Dec;70(6):
pubmed: 32084643
J Bioenerg Biomembr. 2006 Feb;38(1):33-42
pubmed: 16732470
Fertil Steril. 2015 Mar;103(3):605-11
pubmed: 25726702
J Clin Invest. 2001 Oct;108(8):1167-74
pubmed: 11602624
Eur J Endocrinol. 2021 May;184(5):637-645
pubmed: 33635829
BMJ Open Diabetes Res Care. 2020 Apr;8(1):
pubmed: 32332069
Brief Bioinform. 2021 Mar 22;22(2):726-741
pubmed: 33147623
J Am Med Inform Assoc. 2015 May;22(3):553-64
pubmed: 25670757
Front Med (Lausanne). 2020 Nov 11;7:608259
pubmed: 33262996
Lancet Rheumatol. 2020 Jul;2(7):e428-e436
pubmed: 32835246
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):1429-1430
pubmed: 32755846
Lancet. 2009 Nov 14;374(9702):1677-86
pubmed: 19878986
J Am Med Inform Assoc. 2021 Mar 1;28(3):427-443
pubmed: 32805036
Diabetes Res Clin Pract. 2020 Jun;164:108183
pubmed: 32360697
J Clin Med. 2021 Aug 11;10(16):
pubmed: 34441818
Diabetes Care. 2021 Jan;44(Suppl 1):S15-S33
pubmed: 33298413
Appl Clin Inform. 2021 Jan;12(1):57-64
pubmed: 33506478
Trends Microbiol. 2021 Oct;29(10):894-907
pubmed: 33785249
Med Arch. 2013;67(4):282-5
pubmed: 24520755
Nat Rev Dis Primers. 2016 Aug 11;2:16057
pubmed: 27510637
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Diabetes Metab Syndr. 2021 Mar-Apr;15(2):513-518
pubmed: 33662839
Obes Med. 2020 Sep;19:100290
pubmed: 32844132
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741
pubmed: 32228322
Diabetes. 1989 Sep;38(9):1165-74
pubmed: 2670645
Eur J Endocrinol. 2020 Jul;183(1):G33-G39
pubmed: 32438340
Annu Rev Public Health. 2021 Apr 1;42:59-77
pubmed: 33355476
Endocrine. 2006 Aug;30(1):13-7
pubmed: 17185787
Front Immunol. 2020 Aug 18;11:2056
pubmed: 32973814
Open Forum Infect Dis. 2021 Jul 14;8(7):ofab336
pubmed: 34307731
Thyroid. 2021 Feb;31(2):193-201
pubmed: 33003978
Stud Health Technol Inform. 2015;216:574-8
pubmed: 26262116
Drugs. 1991 Apr;41(4):574-95
pubmed: 1711961
J Clin Endocrinol Metab. 2013 Dec;98(12):4565-92
pubmed: 24151290
Lancet Infect Dis. 2020 Aug;20(8):e192-e197
pubmed: 32539990
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Diabetes Care. 2010 Jan;33 Suppl 1:S62-9
pubmed: 20042775
Eur J Gastroenterol Hepatol. 2022 Feb 1;34(2):168-176
pubmed: 33470700
Lancet. 2012 Jun 16;379(9833):2279-90
pubmed: 22683128
Rev Endocr Metab Disord. 2022 Apr;23(2):251-264
pubmed: 35218458
N Engl J Med. 2022 Aug 18;387(7):599-610
pubmed: 36070710
Expert Opin Investig Drugs. 2013 Dec;22(12):1511-7
pubmed: 23978196